of the Epi-Pen? Numerous. Each time the FDA protected Mylan and slow-rolled or rejected the competitive product.
The drug can be duplicated with ease. The device is not revolutionary. The FDA is simply in the way of competition.
of the Epi-Pen? Numerous. Each time the FDA protected Mylan and slow-rolled or rejected the competitive product.
The drug can be duplicated with ease. The device is not revolutionary. The FDA is simply in the way of competition.